Neuland Laboratories (524558) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 total income rose 1.8% year-over-year to INR 401.9 crores, mainly driven by Prime GDS and Specialty business, with marginal topline growth aligning with strategic initiatives in customer acquisition and capacity expansion.

• Profit after tax for Q3 FY25 was INR 101.4 crores, including an exceptional gain of INR 55.8 crores from the sale of investment property.

• FY25 is expected to be flat, with growth anticipated to resume from FY26, supported by a strong order pipeline and customer demand.

• Business remains uneven quarter-to-quarter due to the nature of CDMO and specialty GDS segments.

• Unaudited financial results for the quarter and nine months ended December 31, 2024, were approved by the Board on February 10, 2025.

Financial highlights

• Q3 FY25 EBITDA (excluding exceptional items) was INR 90.3 crores, down from INR 122.7 crores in Q3 FY24, with a margin of 22.5%.

• Gross margin for Q3 was 53.2%, compared to 59.8% in Q3 FY24.

• Nine-month revenue was INR 1161.5 crores, a 1.7% decline year-over-year.

• Free cash flow for nine months was INR 70.8 crores; net debt position is negative INR 185.1 crores.

• Basic and diluted EPS for Q3 FY25 were INR 79.18 (consolidated) and INR 79.03 (standalone), significantly higher than previous quarters.

Outlook and guidance

• FY25 is projected to be flat, consistent with previous guidance.

• Growth is expected to resume in FY26, driven by new commercial molecules and capacity expansion.

• Management remains optimistic about medium- and long-term business momentum, citing strong customer traction and ongoing capacity enhancements, especially in peptides.

• Ongoing investments in peptide capacity and new production blocks are expected to support long-term growth.